Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma

Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA
Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma ( Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA )
12 Oct 2022

ESMO 2022: Lung roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
ESMO 2022: Lung roundup ( Dr Luis Raez -  Memorial Cancer Institute, Miami, USA )
4 Oct 2022

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN

Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN ( Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland )
27 Sep 2022

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
21 Sep 2022

Cancer survivors' stories: An African perspective

Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation
Cancer survivors' stories: An African perspective ( Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation )
15 Sep 2022

ESMO 2022: Breast and ovarian trial analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
14 Sep 2022

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )
14 Sep 2022

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer

Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer ( Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA )
14 Sep 2022

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC

Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC ( Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia )
14 Sep 2022

ESMO 2022: Highlights, commentary and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022

Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer

Prof Chris Parker - Institute of Cancer Research, Sutton, UK
Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )
12 Sep 2022

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC

Dr Silvia Novello - University of Turin, Turin, Italy
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )
12 Sep 2022